EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure
2024-09-03
عنوان الدراسة
EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >40%
داعم الدراسة
Boehringer Ingelheim
دواء الدراسة
BI 690517 , empagliflozin
رقم بروتوكول الدراسة
1378-0020
حالة الدراسة
Ongoing
موقع الدراسة
King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。